Tumor necrosis factor deficiency inhibits mammary tumorigenesis and a tumor necrosis factor neutralizing antibody decreases mammary tumor growth in neu/erbB2 transgenic mice - PubMed (original) (raw)

Tumor necrosis factor deficiency inhibits mammary tumorigenesis and a tumor necrosis factor neutralizing antibody decreases mammary tumor growth in neu/erbB2 transgenic mice

Mary Ann Warren et al. Mol Cancer Ther. 2009 Sep.

Abstract

Tumor necrosis factor-alpha (TNF-alpha) is a pleiotropic cytokine that is synthesized and secreted by cells of the immune system, as well as by certain epithelia and stroma. Based on our previous studies demonstrating TNF-stimulated proliferation of normal and malignant mammary epithelial cells, we hypothesized that TNF might promote the growth of breast cancer in vivo. To test this, we generated bigenic mice that overexpressed activated neu/erbB2 in the mammary epithelium and whose TNF status was wild-type, heterozygous, or null. Mammary tumorigenesis was significantly decreased in TNF-/- mice (n = 30) compared with that in TNF+/+ mice (n = 27), with a palpable tumor incidence of 10.0% and 44.4%, and palpable tumors/mouse of 0.10 +/- 0.06 and 0.67 +/- 0.17, respectively. Tumorigenesis in the heterozygous group fell between that in the TNF+/+ and TNF-/- groups, but was not significantly different from either of the homozygous groups. The decreased tumor development in the TNF-/- mice was associated with a decreased proliferative index in the lobular and ductal mammary epithelium. To further investigate the role of TNF in breast cancer, mammary tumor-bearing mice whose tumors overexpressed wild-type neu/erbB2 were treated with a TNF-neutralizing antibody or a control antibody for 4 weeks (n = 20/group). Mammary tumor growth was significantly inhibited in mice treated with the anti-TNF antibody compared with the control antibody. Together, these data show a stimulatory role for TNF in the growth of breast tumors and suggest that TNF antagonists may be effective in a subset of patients with breast cancer.

PubMed Disclaimer

Cited by

AP-1-mediated chromatin looping regulates ZEB2 transcription: new insights into TNFα-induced epithelial-mesenchymal transition in triple-negative breast cancer.
Qiao Y, Shiue CN, Zhu J, Zhuang T, Jonsson P, Wright AP, Zhao C, Dahlman-Wright K. Qiao Y, et al. Oncotarget. 2015 Apr 10;6(10):7804-14. doi: 10.18632/oncotarget.3158. Oncotarget. 2015. PMID: 25762639 Free PMC article.
TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype.
Storci G, Sansone P, Mari S, D'Uva G, Tavolari S, Guarnieri T, Taffurelli M, Ceccarelli C, Santini D, Chieco P, Marcu KB, Bonafè M. Storci G, et al. J Cell Physiol. 2010 Nov;225(3):682-91. doi: 10.1002/jcp.22264. J Cell Physiol. 2010. PMID: 20509143 Free PMC article.
The inflammatory cytokine TNFα cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells.
Leibovich-Rivkin T, Liubomirski Y, Meshel T, Abashidze A, Brisker D, Solomon H, Rotter V, Weil M, Ben-Baruch A. Leibovich-Rivkin T, et al. BMC Cancer. 2014 Mar 6;14:158. doi: 10.1186/1471-2407-14-158. BMC Cancer. 2014. PMID: 24598028 Free PMC article.
Microenvironmental networks promote tumor heterogeneity and enrich for metastatic cancer stem-like cells in Luminal-A breast tumor cells.
Weitzenfeld P, Meshel T, Ben-Baruch A. Weitzenfeld P, et al. Oncotarget. 2016 Dec 6;7(49):81123-81143. doi: 10.18632/oncotarget.13213. Oncotarget. 2016. PMID: 27835603 Free PMC article.
Hyperbaric oxygen therapy sensitizes nimustine treatment for glioma in mice.
Lu Z, Ma J, Liu B, Dai C, Xie T, Ma X, Li M, Dong J, Lan Q, Huang Q. Lu Z, et al. Cancer Med. 2016 Nov;5(11):3147-3155. doi: 10.1002/cam4.851. Epub 2016 Oct 13. Cancer Med. 2016. PMID: 27734611 Free PMC article.

Tumor necrosis factor deficiency inhibits mammary tumorigenesis and a tumor necrosis factor neutralizing antibody decreases mammary tumor growth in neu/erbB2 transgenic mice - PubMed (original) (raw)